Abstract
Neovascularization is often required for rapid growth of solid tumors and also limits vascular metastasis of tumor cells. Neovascularization-targeting agents are a recent innovation that may be a novel means of anticancer therapy. These antiangiogenic drugs have been developed by targeting cell proliferation of vascular endothelial cells, basement-membrane-degrading enzymes, angiogenic factors/receptors, extracellular matrix, angiogenesis signaling, and cell-cell/cell-matrix interactions. In this report, we describe how tumor angiogenesis occurs and how antiangiogenic agents are developed.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ono, M., Izumi, H., Yoshida, S. et al. Angiogenesis as a new target for cancer treatment. Cancer Chemother Pharmacol 38 (Suppl 1), S78–S82 (1996). https://doi.org/10.1007/s002800051044
Issue Date:
DOI: https://doi.org/10.1007/s002800051044